As previously reported, Craig-Hallum initiated coverage of Myriad Genetics (MYGN) with a Buy rating and $29 price target. The firm believes the ...

SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...

Myriad Genetics, Inc., a leader in genetic and tumour genomic testing and precision medicine, announced that the United States Patent and Trademark Office (USPTO) issued two new patents that further ...